347 related articles for article (PubMed ID: 36735180)
1. The Therapeutic Potential of Antioxidants in Chemotherapy-Induced Peripheral Neuropathy: Evidence from Preclinical and Clinical Studies.
Zhou L; Yang H; Wang J; Liu Y; Xu Y; Xu H; Feng Y; Ge W
Neurotherapeutics; 2023 Mar; 20(2):339-358. PubMed ID: 36735180
[TBL] [Abstract][Full Text] [Related]
2. Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial.
Clavo B; Martínez-Sánchez G; Rodríguez-Esparragón F; Rodríguez-Abreu D; Galván S; Aguiar-Bujanda D; Díaz-Garrido JA; Cañas S; Torres-Mata LB; Fabelo H; Téllez T; Santana-Rodríguez N; Fernández-Pérez L; Marrero-Callico G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802143
[TBL] [Abstract][Full Text] [Related]
3. Antioxidants Improve Oxaliplatin-Induced Peripheral Neuropathy in Tumor-Bearing Mice Model: Role of Spinal Cord Oxidative Stress and Inflammation.
Agnes JP; Santos VWD; das Neves RN; Gonçalves RM; Delgobo M; Girardi CS; Lückemeyer DD; Ferreira MA; Macedo-Júnior SJ; Lopes SC; Spiller F; Gelain DP; Moreira JCF; Prediger RD; Ferreira J; Zanotto-Filho A
J Pain; 2021 Aug; 22(8):996-1013. PubMed ID: 33774154
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy.
Areti A; Yerra VG; Naidu V; Kumar A
Redox Biol; 2014; 2():289-95. PubMed ID: 24494204
[TBL] [Abstract][Full Text] [Related]
5. Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms.
Hu LY; Mi WL; Wu GC; Wang YQ; Mao-Ying QL
Curr Neuropharmacol; 2019; 17(2):184-196. PubMed ID: 28925884
[TBL] [Abstract][Full Text] [Related]
6. Medicinal plants and their isolated phytochemicals for the management of chemotherapy-induced neuropathy: therapeutic targets and clinical perspective.
Oveissi V; Ram M; Bahramsoltani R; Ebrahimi F; Rahimi R; Naseri R; Belwal T; Devkota HP; Abbasabadi Z; Farzaei MH
Daru; 2019 Jun; 27(1):389-406. PubMed ID: 30852764
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-Induced Peripheral Neuropathy: Causative Agents, Preventative Strategies, and Treatment Approaches.
Kachrani R; Santana A; Rogala B; Pawasauskas J
J Pain Palliat Care Pharmacother; 2020 Sep; 34(3):141-152. PubMed ID: 32118502
[TBL] [Abstract][Full Text] [Related]
8. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update.
Desforges AD; Hebert CM; Spence AL; Reid B; Dhaibar HA; Cruz-Topete D; Cornett EM; Kaye AD; Urits I; Viswanath O
Biomed Pharmacother; 2022 Mar; 147():112671. PubMed ID: 35104697
[TBL] [Abstract][Full Text] [Related]
9. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review.
Schloss JM; Colosimo M; Airey C; Masci PP; Linnane AW; Vitetta L
Clin Nutr; 2013 Dec; 32(6):888-93. PubMed ID: 23647723
[TBL] [Abstract][Full Text] [Related]
10. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
11. A Narrative Review of Complementary Nutritional Supplements for Chemotherapy-induced Peripheral Neuropathy.
Liu YW; Liu CT; Su YL; Tsai MY
Altern Ther Health Med; 2020 Jul; 26(4):43-49. PubMed ID: 31634876
[TBL] [Abstract][Full Text] [Related]
12. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Hoshino N; Ganeko R; Hida K; Sakai Y
Int J Clin Oncol; 2018 Jun; 23(3):434-442. PubMed ID: 29270698
[TBL] [Abstract][Full Text] [Related]
13. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Kuriyama A; Endo K
Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
[TBL] [Abstract][Full Text] [Related]
14. Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices.
Selvy M; Pereira B; Kerckhove N; Busserolles J; Farsi F; Guastella V; Merle P; Pezet D; Balayssac D
Support Care Cancer; 2021 Jul; 29(7):4033-4043. PubMed ID: 33403401
[TBL] [Abstract][Full Text] [Related]
15. [Chinese expert consensus on the diagnosis and treatment of chemotherapy-induced peripheral neuropathy (2022 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):928-934. PubMed ID: 36164693
[TBL] [Abstract][Full Text] [Related]
16. Prevention of anticancer therapy-induced neurotoxicity: Putting DNA damage in perspective.
Brinkmann V; Fritz G
Neurotoxicology; 2022 Jul; 91():1-10. PubMed ID: 35487345
[TBL] [Abstract][Full Text] [Related]
17. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review.
Flatters SJL; Dougherty PM; Colvin LA
Br J Anaesth; 2017 Oct; 119(4):737-749. PubMed ID: 29121279
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer.
Teng C; Cohen J; Egger S; Blinman PL; Vardy JL
Support Care Cancer; 2022 Jan; 30(1):33-47. PubMed ID: 34410459
[TBL] [Abstract][Full Text] [Related]
19. Melittin, a honeybee venom derived peptide for the treatment of chemotherapy-induced peripheral neuropathy.
Tender T; Rahangdale RR; Balireddy S; Nampoothiri M; Sharma KK; Raghu Chandrashekar H
Med Oncol; 2021 Apr; 38(5):52. PubMed ID: 33796975
[TBL] [Abstract][Full Text] [Related]
20. Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms.
Argyriou AA; Bruna J; Park SB; Cavaletti G
Expert Rev Neurother; 2020 Oct; 20(10):1005-1016. PubMed ID: 32667212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
